anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
General  
Folic acid when administered as a single agent in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. The 2 mgs of B12 (cyanocobalamin), the amount contained in Methaver, has been shown to provide an adequate amount of B12 to address this precaution. Unmetabolized folic acid has been shown in one study of 105 postmenopausal women (50-75 yrs) to have the potential to reduce natural killer cells’ cytotoxicity, which may result in an impaired immune response.

B12 should not be used in those with Leber’s optic atrophy. Decreased levels of B have been associated with reduced ability to detoxify the cyanide in exposed individuals and B may increase the risk of irreversible neurological damage from optic atrophy in those affected with the disorder. Hydroxocobalamin can aid in the detoxification of cyanide. This form of B12, although not in this product, is an acceptable form for >B12 supplementation in those with this disorder.

Caution should be exercised when Methaver is administered to patients with diabetic nephropathy. One published study showed that among patients with diabetic nephropathy given high dose folic acid, vitamin B12, and vitamin B (pyridoxine) versus a placebo, there was a greater decrease in glomerular filtration rate (GRF).

Pregnant women and nursing mothers may be recommended to use 12 microgram doses of B12 from nutritional supplements, although higher doses should only be taken on the recommendations of a prescribing medical professional. Administration of doses of vitamin B12 greater than 10 micrograms daily may produce a hematological response in those with anemia secondary to folate deficiency.

Folate, when administered as a sing le agent in doses about 0.1 mg daily, may obscure the detection of vitamin B12 deficiency (specifically, the administration of folic acid may reverse the hematological manifestations of B12 deficiency, including pernicious anemia, while not addressing the neurological manifestations).

Folate therapy alone is inadequate for treatment of a vitamin B12 deficiency.
OBJECTIVE: This study investigates the predictive role of indocyanine green angiography and thermography in assessing mastectomy skin flap necrosis in the intraoperative and postoperative setting.
METHODS: A retrospective review of 45 patients who underwent nipple-sparing mastectomy and immediate prepectoral reconstruction was performed. Mastectomy flap viability was evaluated intraoperatively with indocyanine green angiography and thermography after placement of an implant sizer and again postoperatively at 24 hours. Fluorescence pattern was analyzed with a near-infrared camera (IC-FlowTM Imaging System, Diagnostic Green GmbH, Germania) and thermographic images with FLIR ONE device. FLIR ONE and ICG images were then transposed on macroscopic breast images with a scale 1:1. The mastectomy skin flap was evaluated using the SKIN score (Mayo Clinic Classification).
RESULTS: Overlap between angiography and thermography images was 87.95% intraoperatively and 95.95% 24 hours postoperatively. Overlay with mastectomy flap necrosis was higher in the intraoperative angiography group with statistical significance. Contrarily, such a difference was not apparent in the postoperative period.
CONCLUSIONS: ICG appears to be a superior tool when used intraoperatively with fundamental implications on reconstructive decision-making, while thermography could be a valuable assessment method in the postoperative setting. Further studies are necessary to confirm such results and determine their clinical applicability.
Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
Newborn or Premature Infants: This drug should not be used in newborn or premature infants. 

  
Nursing Mothers: Because of the higher risk of antihistamines for infants generally, and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. 

  
Other Conditions: Hypersensitivity to cyproheptadine and other drugs of similar chemical structure. Monoamine oxidase inhibitor therapy (see DRUG INTERACTIONS). Angle-closure glaucoma. Stenosing peptic ulcer. Symptomatic prostatic hypertrophy. Bladder neck obstruction. Pyloroduodenal obstruction, elderly, debilitated patients.
Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Available evidence suggests that AMD is a complex disorder with a significant genetic component as well as potential environmental influences. In this study we propose to examine 3,000 members, ages 50 and older, of the Old Order Amish community in the Lancaster and Franklin counties area in Pennsylvania. We plan to detail the epidemiology of AMD in this population isolate in attempt to elucidate genetic factors which may confer susceptibility and predispose some Amish individuals and their families to develop AMD. All study participants agreeing to enroll and providing informed consent will undergo a complete, dilated eye examination during which digital stereo images of the macula and optic disc regions will be acquired. Study participants will also be asked to complete a brief questionnaire inquiring about personal exposures related to occupation, sunlight, and smoking. AMD will be determined by an independent reading of the digital fundus photographs by the University of Wisconsin Fundus Photography Reading Center according to the AREDS AMD classification scheme. We will employ standard statistical genetics methods of parametric and non-parametric linkage analysis, association analysis, and transmission disequilibrium tests, with allowances for environmental (i.e. non-genetic) factors to determine if we can identify any candidate regions or candidate genes that predispose Amish individuals to an increased risk of AMD. Ultimately, we hope to follow up any regions that show suggestive evidence of linkage on the genome-wide scan with fine mapping in those regions, leading to eventual cloning and sequencing of a gene or genes.
PURPOSE: A system for preparing a medical treatment electronic chart using a voice recognition is provided to make a chart for inquiring a clinical history through a voice recognition unit and prepare an electronic chart. CONSTITUTION: Information of a speaker is stored according to medical terms being used in each examination room of a hospital(1). As a user executes a voice command using a microphone, the voice command is executed(2). The voice recognized contents are mapped on a monitor(3). The voice command displayed on the monitor is inputted in a chart(4). A wave value of the voice is analyzed, and the voice command is compared and searched for matching with a prescription term on the monitor(5). The compared and searched prescription term is stored in a chart electronically(6).
BACKGROUND: The formation of adhesion after tendon injury represents a major obstacle to tendon repair, and currently there is no effective anti-adhesion method in clinical practice. Oxidative stress, inflammation, and fibrosis can occur in tendon injury and these factors can lead to tendon adhesion. Antioxidant carbon dots and ursolic acid (UA) both possess antioxidant and anti-inflammatory properties. In this experiment, we have for the first time created RCDs/UA@Lipo-HAMA using red fluorescent carbon dots and UA co-encapsulated liposomes composite hyaluronic acid methacryloyl hydrogel. We found that RCDs/UA@Lipo-HAMA could better attenuate adhesion formation and enhance tendon healing in tendon injury.
MATERIALS AND METHODS: RCDs/UA@Lipo-HAMA were prepared and characterized. In vitro experiments on cellular oxidative stress and fibrosis were performed. Reactive oxygen species (ROS), and immunofluorescent staining of collagens type I (COL I), collagens type III (COL III), and α-smooth muscle actin (α-SMA) were used to evaluate anti-oxidative and anti-fibrotic abilities. In vivo models of Achilles tendon injury repair (ATI) and flexor digitorum profundus tendon injury repair (FDPI) were established. The major organs and blood biochemical indicators of rats were tested to determine the toxicity of RCDs/UA@Lipo-HAMA. Biomechanical testing, motor function analysis, immunofluorescence, and immunohistochemical staining were performed to assess the tendon adhesion and repair after tendon injury.
RESULTS: In vitro, the RCDs/UA@Lipo group scavenged excessive ROS, stabilized the mitochondrial membrane potential (ΔΨm), and reduced the expression of COL I, COL III, and α-SMA. In vivo, assessment results showed that the RCDs/UA@Lipo-HAMA group improved collagen arrangement and biomechanical properties, reduced tendon adhesion, and promoted motor function after tendon injury. Additionally, the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) in the RCDs/UA@Lipo-HAMA group increased; the levels of cluster of differentiation 68 (CD68), inducible Nitric Oxide Synthase (iNOS), COL III, α-SMA, Vimentin, and matrix metallopeptidase 2 (MMP2) decreased.
CONCLUSION: In this study, the RCDs/UA@Lipo-HAMA alleviated tendon adhesion formation and enhanced tendon healing by attenuating oxidative stress, inflammation, and fibrosis. This study provided a novel therapeutic approach for the clinical treatment of tendon injury.
The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
A gas-tight pharmaceutical container includes a pharmaceutical bottle defining a main enclosure and an upper neck forming a top opening. The upper neck includes an upper rim forming a planar engagement surface. A screw-on closure cap seals the top opening, and includes a circular top member and a circumferential flange. In one embodiment, the closure cap is metal and includes an annular pliable gasket secured to a peripheral portion thereof and a layer of lacquer applied interiorly of the gasket. In another embodiment, the closure cap is plastic and includes a circular inner liner formed by a base layer, a foil layer adjacent to the base layer, and an annular pliable gasket secured to the foil layer. With either embodiment, threaded engagement of the screw-on closure cap with the pharmaceutical bottle under pressure causes the pliable gasket to sealingly engage the upper rim to provide a gas-tight seal.
The invention relates to highland barley source active oligopeptide, a preparation method and application thereof. The highland barley active oligopeptide has any one or more of P1, P2 and P3, wherein the amino sequence of P1 is Pro-Asp-Leu-Pro (PDLP), P2 is Tyr-Arg-Ile-Val-Pro-Leu (YRIVPL), and P3 is Val-Phe-Leu-Gln-Pro-His (VFLQPH). The active oligopeptide can remarkably increase the secretion of cholecystokinin (CCK) by intestinal endocrine cells. The active oligopeptide can be obtained by enzymolysis of highland barley protein and then separation and purification, and can also be synthesized artificially by adopting a chemical solid phase synthesis method. The active oligopeptide disclosed by the invention not only can obviously stimulate endocrine cells of intestinal tracts to secrete CCK, but also has the characteristics of safety, no toxic or side effect, difficulty in degradation by digestive enzymes of the gastrointestinal tracts, easiness in absorption and the like. The active oligopeptide can be used as a functional component to be applied to the development of medicines with the functions of delaying gastric emptying, promoting satiety and losing weight, and has high application value in the fields of medicines and the like and broad prospect.
In group (B) (OBA) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
INTRODUCTION: Biomarkers that could reliably anticipate the effectiveness of antihistamines and omalizumab in treating chronic spontaneous urticaria (CSU) have not been conclusively identified. Our objective was to examine how eosinophilic cationic protein (ECP), tryptase, D-dimer, and total Immunoglobulin E (IgE) impact the response to antihistamine and omalizumab treatments in individuals with CSU.
METHODS: In this cross-sectional retrospective study, CSU patients that had undergone treatment with either antihistamines or omalizumab for a minimum of 12 weeks between 2015 and 2021 at an Allergy and Immunology Department were analyzed. Several demographic and laboratory parameters including eosinophil counts, mean platelet volüme (MPV), sedimentation, C-reactive protein (CRP), antinuclear antibodies (ANA) and Anti-thyroperoxidase (Anti-TPO) and total IgE, tryptase, ECP and D-dimer were retrived from patient files. The association of these biomarkers with Urticaria Control Test (UCT) and the effect of these biomarkers on treatment response were evaluated. Treatment response was assessed using the UCT, with a score of UCT ≥ 12 indicating a responder and UCT < 12 indicating a non responder.
RESULTS: The patients in the omalizumab group were older, had a longer disease duration and had worse urticaria control (lower baseline UCT scores). 421 patients were treated with antihistamines and 88 patients were treated with omalizumab. ECP was found to be inversely correlated with baseline UCT (p < 0.001 r=-0.268). ECP and D-dimer levels of non-responder patients in the antihistamine group were significantly higher than in responder patients (ECP: 49 ng/mL vs 28.1 ng/mL, p < 0.001) (D-dimer: 0.60 mg/L vs 0.30 mg/L, p < 0.001), while there were no significant difference in terms of tryptase and total IgE. These four biomarkers were similar, in omalizumab responders and non responders.
CONCLUSION: In this study with CSU, we looked at predictors of responses to treatments. ECP can serve as a marker of poor urticaria control and may predict antihistamine refractoriness along with D-dimer.
PCT No. PCT/JP93/00868 Sec. 371 Date Feb. 3, 1994 Sec. 102(e) Date Feb. 3, 1994 PCT Filed Jun. 25, 1993 PCT Pub. No. WO94/00094 PCT Pub. Date Jan. 6, 1994.A composition for treating keratinous fibers, which comprises: (A) A first agent containing a metal ion, (B) A second agent comprising: (B-1) An organic or inorganic compound which is capable of readily permeating into the keratinous fibers and can form water-insoluble or sparingly soluble complex together with said metal ion of component (A), and (B-2) An organic compound which cannot readily permeate into the keratinous fibers, and which reacts with said metal ion of component (A) to form a water-soluble complex, and method for treating keratinous fibers utilizing the composition. When the composition according to the present invention is used for treating keratinous fibers, it allows water-insoluble or sparingy soluble complex products to deposit inside the keratinous fibers while preventing water-insoluble or sparingly soluble complex products from depositing on the surface of the keratinous fibers. Because of this mechanism, the present composition is capable of imparting sufficient firmness and elasticity to keratinous fibers without inducing any objectionable rough or frictional feel to the touch of the hair.
Renal toxicity ranging from elevated serum creatinine to renal failure and death have been reported in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents for non-MDS conditions. In addition, renal tubular acidosis, defined as a fall in serum bicarbonate to <20 mEq/L in association with an alkaline urine and hypokalemia (serum potassium <3 mEq/L) developed in 5 patients with CML treated with azacitidine and etoposide. Monitor serum creatinine and electrolytes prior to initiation of therapy and with each cycle. If unexplained reductions in serum bicarbonate <20 mEq/L or elevations of BUN or serum creatinine occur, reduce or hold the dose [see Dosage and Administration ( 2.6)] . 

Patients with renal impairment may be at increased risk for renal toxicity. Also, azacitidine and its metabolites are primarily excreted by the kidney. Therefore, monitor these patients closely for toxicity [see Dosage and Administration ( 2.6, 2.7)] . Patients with MDS and renal impairment were excluded from the clinical studies. 

Pediatric use information is approved for Bristol-Myers Squibb Company’s Vidaza (azacitidine for injection). However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.
Addiction is defined as a chronic, relapsing disorder characterized by compulsive drug seeking and use despite adverse consequences. Pathological substance use disorders represent a major public health crisis with limited effective treatment options. Although the gut and brain are separate organs, they communicate with each other via trillions of intestinal bacteria that collectively make up one's gut microbiome. Findings from both humans and animals support a critical role of gut microbes in regulating brain function, mood, and behavior. Gut bacteria influence neural circuits that are notably affected in addiction-related behaviors. These include circuits involved in stress, reward, and motivation, with substance use influencing gut microbial abnormalities, suggesting significant gut-brain interactions in drug addiction.

The investigator will discuss this role of gut microbiome in Assuit university hospital to see how the pathogenesis can be altered of drug addiction.
The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
A method includes generating first contrast significance data for a first computer vision model generated from a first training set of medical scans. First significant contrast parameters are identified based on the first contrast significance data. A first re-contrasted training set is generated based on performing a first intensity transformation function on the first training set of medical scans, where the first intensity transformation function utilizes the first significant contrast parameters. A first re-trained model is generated from the first re-contrasted training set, which is associated with corresponding output labels based on abnormality data for the first training set of medical scans. Re-contrasted image data of a new medical scan is generated based on performing the first intensity transformation function. Inference data indicating at least one abnormality detected in the new medical scan is generated based on utilizing the first re-trained model on the re-contrasted image data.
Previous studies that performed a comparative analysis of physical activity between individuals with and without stroke have consistently reported that stroke survivors tend to spend less time in moderate to vigorous physical activity The 2021 AHA guideline recommends smaller sessions of PA, with suggestions such as 10 minutes of moderate activity, 4 times a week, or 20 minutes of vigorous activity twice a week. This contrasts the weekly physical activity recommendations in 2011 (30 minutes of moderate to vigorous, 1 to 3 times) and 2014 (40 minutes of moderate to vigorous, 3 to 4 times). We hypothesise that older stroke survivors are physically active more frequently but for smaller durations than younger stroke survivors who are physically active for longer durations but less regularly. Understanding these subtle changes will not only help to tailor physical activity interventions based on specific recommendations but also help design future recommendations.

Moderate-to-vigorous PA could be an adequate approach for stroke survivors as it requires less time to achieve the same benefits as light PA. More concretely, a new concept called moderate-to-vigorous intermittent lifestyle physical activity (MV-ILPA) has recently emerged for adults who do not habitually exercise in their leisure time. MV-ILPA refers to brief and sporadic bouts of moderate-vigorous intensity PA performed as part of the activities of daily living, such as bursts of very fast walking, sitting and standing up from a chair, or stair climbing. MV-ILPA is associated with a substantially lower risk of all-cause cardiovascular disease and cancer mortality. However, there is no evidence to directly support the potential benefits of MV-ILPA in the elderly post-stroke patients.
IMPORTANCE: Several public recommendations exist regarding the amount of daily water intake, yet the supporting evidence is not clear, and benefits of increasing water consumption are not well-established.
OBJECTIVE: To summarize evidence from randomized clinical trials (RCTs) pertaining to the health-related outcomes associated with increased or decreased daily water consumption.
EVIDENCE REVIEW: A systematic search of PubMed, Web of Science, and Embase was performed up to April 6, 2023. Studies were included if they aimed to assess the impact of daily water consumption by any defined amount on any health-related outcome.
FINDINGS: Of 1464 records screened, 18 (1%) eligible studies were included in the review. Among eligible studies, 15 (83%) were parallel group RCTs, and 3 (16%) were crossover studies. Interventions in these studies consisted of a recommendation to alter the daily amount of water intake by a specific amount for a predefined period ranging between 4 days and 5 years, while the control groups were mostly asked to maintain their usual intake habits. The studies assessed various populations. Recurring primary end points included weight loss, fasting blood glucose level, headache, urinary tract infection, and nephrolithiasis. Consuming additional water was associated with greater weight loss (range, 44%-100% more than control conditions) and fewer nephrolithiasis events (15 fewer events per 100 participants over 5 years). Single studies suggested benefits related to migraine prevention, urinary tract infection, diabetes control, and hypotension. Ten studies (55%) reported at least 1 positive result, and 8 studies (44%) reported negative results.
CONCLUSIONS AND RELEVANCE: This systematic review found that there is a limited number of clinical trials in the literature assessing the benefits of increasing water intake related to a large variety of health outcomes. While the quality and quantity of evidence is limited, a small number of studies suggested benefits of water intake on weight loss and nephrolithiasis, while single studies raised the possibility of benefits for patients with migraine, urinary tract infection, diabetes, and hypotension. Given the low cost and low adverse-effect profile of water, further well-designed studies should assess benefits in these specific conditions.